2607 (2607) Fair Value & Analysis

Healthcare · Market cap HK$42.6B

2 2607 2607 · HK

PriceHK$11.49

Fair ValueHK$39.20

Upside+241.2%

Quality56/100

Watch 2607 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$29.40 – HK$49.00

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −1.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$11.07 – HK$12.69 · fair‑value band HK$29.40 – HK$49.00 · the HK$11.49 price screens below the HK$39.20 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2607 (2607) currently trades at HK$11.49, while our model-based Fair Value estimate is HK$39.20 — implying the stock looks roughly 241.2% undervalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 2607 generated revenue of HK$288B at a net margin of 2.0%. Revenue grew 6.4% year over year. It earns a return on equity of 8.1%. Net debt stands at HK$16.8B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$288B

Revenue growth (YoY) +6.4%

Net margin 2.0%

Return on equity 8.1%

Free cash flow HK$3.8B FY2025

P/E ratio 6.4

More key figures

Operating margin 3.5%

EPS (TTM) HK$1.39

Dividend yield 4.1%

EPS growth (YoY) +6.3%

Net debt HK$16.8B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2607 reported revenue of HK$284B in FY2025 versus HK$216B in FY2021, a compound +7.1%/yr. Reported net income was HK$5.7B in FY2025, compounding +3.0%/yr from FY2021.

Revenue +7.1%/yr

FY21 HK$216B

FY22 HK$232B

FY23 HK$260B

FY24 HK$275B

FY25 HK$284B

Net income +3.0%/yr

FY21 HK$5.1B

FY22 HK$5.6B

FY23 HK$3.8B

FY24 HK$4.6B

FY25 HK$5.7B

Is 2607 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$958.36	R$188.90	-80%
Cencora, Inc C1CO34	R$709.32	R$400.31	-44%
Cardinal Health, Inc CAH	$222.74	$141.77	-36%
Sigma Healthcare Limited SIGGF	$2.35	$0.7800	-67%
SIG SIG	A$2.76	A$0.3300	-88%
Shanghai Pharmaceuticals Holding 601607	¥15.96	¥56.73	+255%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2607 (2607) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$39.20 versus a price of HK$11.49 — about +241% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2607?

Our model-based fair value for 2607 is HK$39.20 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$11.49.

What is the quality score of 2607?

2607 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2607 (2607)?

2607 reported trailing-twelve-month revenue of about HK$288B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2607?

The net profit margin of 2607 is about 2.0%, meaning it keeps roughly 2.0% of revenue as net income. Based on the latest reported figures.

Does 2607 pay a dividend?

2607 currently shows a dividend yield of about 4.12% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.